Keywords : thyroid cancer, Medullary thyroid cancer, cancer
This report provides information on the therapeutic development for Medullary Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer. 'Medullary Thyroid Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /Univ...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides information on the therapeutic development for Medullary Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer. 'Medullary Thyroid Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Medullary Thyroid Cancer.
- A review of the Medullary Thyroid Cancer products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Medullary Thyroid Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Medullary Thyroid Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Global Pathology Industry
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global March kets Direct Report Coverage 5
Medullary Thyroid Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Medullary Thyroid Cancer 7
Medullary Thyroid Cancer Therapeutics under Development by Firms 9
Medullary Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Medullary Thyroid Cancer Therapeutics – Products under Development by Firms 15
Medullary Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Medullary Thyroid Cancer Therapeutics Development 17
November artis AG 17
Exelixis, Inc. 18
Globeimmune, Inc. 19
Medullary Thyroid Cancer – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Afinitor - Drug Profile 26
Cabozantinib - Drug Profile 28
Gleevec + Dacarbazine + Xeloda - Drug Profile 30
ZD6474 - Drug Profile 31
GI-6207 - Drug Profile 32
Gleevec - Drug Profile 33
Pazopanib Hydrochloride - Drug Profile 34
Tanespimycin - Drug Profile 36
Lithium Carbonate - Drug Profile 38
Afinitor - Drug Profile 39
LBH589 - Drug Profile 40
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 41
Aplidin - Drug Profile 43
Prednisone + Thalidomide - Drug Profile 44
Sorafenib Tosylate - Drug Profile 46
Sunitinib - Drug Profile 47
Sutent - Drug Profile 48
Pasireotide LAR + Everolimus - Drug Profile 49
Thalidomide - Drug Profile 51
Medullary Thyroid Cancer Therapeutics – Drug Profile Updates 52
Medullary Thyroid Cancer Therapeutics - Dormant Products 59
Medullary Thyroid Cancer – Product Development Milestones 60
Featured News & Press Releases 60
Appendix 67
Methodology 67
Expert Panel Validation 68
Contact Us 68
Disclaimer 68
List of Tables
Number of Products Under Development for Medullary Thyroid Cancer, H1 2012 8
Products under Development for Medullary Thyroid Cancer – Comparative Analysis, H1 2012 9
Number of Products under Development by Firms, H1 2012 10
Number of Products under Investigation by Universities/Institutes, H1 2012 12
Comparative Analysis by Late Stage Development, H1 2012 13
Comparative Analysis by Mid Clinical Stage Development, H1 2012 14
Comparative Analysis by Early Clinical Stage Development, H1 2012 15
Products under Development by Firms, H1 2012 16
Products under Investigation by Universities/Institutes, H1 2012 17
November artis AG, H1 2012 18
Exelixis, Inc., H1 2012 19
Globeimmune, Inc., H1 2012 20
Assessment by Monotherapy Products, H1 2012 21
Assessment by Combination Products, H1 2012 22
Assessment by Stage and Route of Administration, H1 2012 24
Assessment by Molecule Type, H1 2012 26
Medullary Thyroid Cancer Therapeutics – Drug Profile Updates 53
Medullary Thyroid Cancer Therapeutics – Dormant Products 60
List of Figures
Number of Products under Development for Medullary Thyroid Cancer, H1 2012 8
Products under Development for Medullary Thyroid Cancer – Comparative Analysis, H1 2012 9
Products under Development by Firms, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 11
Late Stage Products, H1 2012 13
Mid Clinical Stage Products, H1 2012 14
Early Clinical Stage Products, H1 2012 15
Assessment by Monotherapy Products, H1 2012 21
Assessment by Combination Products, H1 2012 22
Assessment by Route of Administration, H1 2012 23
Assessment by Stage and Route of Administration, H1 2012 24
Assessment by Molecule Type, H1 2012 25
Assessment by Stage and Molecule Type, H1 2012 26
